We clarified the performance of a cryptococcal glucuronoxylomannan (GXM) antigen test using bronchoalveolar lavage fluid (BALF) samples, in an HIV-negative Japanese population. Between March 2008 and December 2014, we examined cryptococcal GXM antigens in both serum and BALF specimens from 429 cases at Nagasaki University hospital. The diagnoses, underlying diseases, chest computed tomography findings, and cryptococcal GXM antigen test results were retrospectively investigated. Twenty-three patients were confirmed to have pulmonary cryptococcosis, another six were clinically diagnosed with cryptococcosis because they were seropositive for the GXM antigen, and five possible cryptococcosis cases had BALF samples that were positive for the GXM antigen and serum samples that were negative. The test's sensitivities for detecting cryptococcal GXM antigens in serum and BALF samples, for confirmed cases, were 73.9% and 82.6%, respectively, and their respective specificities were 98.5% and 97.8%. Three of the five putative patients with cryptococcosis were treated with antifungal agents; the pulmonary lesions decreased in size in all treated patients. Both the BALF and serum GXM antigen titers showed positive correlations with the lesion sizes; however, the Oshima et al.
Introduction
The primary site for Cryptococcus neoformans infections is the lung, but the infection may disseminate throughout the body, including into the central nervous system, skin, and bones. 1 Cryptococcus is also one of the major opportunistic pathogens in patients with AIDS. 2 Although the nationwide surveillance program has not been completed, cryptococcosis is believed to be the third most common cause of mycoses in Japan, according to the 2009 pathological autopsy data. 3 The Japanese Ministry of Health, Labor, and Welfare reported that the cumulative number of human immunodeficiency virus (HIV)-positive patients in Japan was approximately 26,000, at the end of 2015. Therefore, the prevalence of HIV in Japan is estimated to be approximately 0.02%, much lower than in other global regions, according to UNAIDS (http://www.unaids.org/sites/ default/files/media asset/global-AIDS-update-2016 en.pdf). Therefore, the proportion of HIV-negative patients with pulmonary cryptococcosis is relatively higher in Japan than in other countries. One possible reason for the high rate of detection of asymptomatic pulmonary cryptococcosis cases may be the relatively high frequency of computed tomography (CT) scans performed in Japan. 4 Since the mortality and morbidity rates associated with cryptococcal cerebromeningitis are high, good outcomes are dependent on the early diagnosis of and specific therapy for cryptococcosis. A definite pulmonary cryptococcosis diagnosis is based on culture results or on histopathological and cytological findings; however, the sensitivity of these examinations for C. neoformans is relatively low owing to the difficulties associated with obtaining adequate specimens. Additionally, obtaining culture results requires at least 1 week. 5, 6 However, only 2 h are required to obtain the results from cryptococcal glucuronoxylomannan (GXM) antigen tests. Since serum cryptococcal GXM antigen tests are highly sensitive in diagnosing pulmonary cryptococcosis, they are used as adjuncts to the clinical diagnosis of pulmonary cryptococcosis. 7, 8 Unfortunately, serum cryptococcal GXM antigen test results tend to be negative if the size of the pulmonary lesion is <15 mm. 9 As a result, pulmonary cryptococcosis is often misdiagnosed as lung cancer because the radiologic findings are similar to those of lung cancers 10, 11 ; conclusive diagnoses, in such cases are often only made following surgery. Therefore, early diagnosis of pulmonary cryptococcosis can help avoid unnecessary invasive procedures. Thus, new diagnostic aids are needed to diagnose pulmonary cryptococcosis cases when the pulmonary lesions are small. We hypothesized that the presence of cryptococcal GXM antigen in bronchoalveolar lavage fluid (BALF) may enable the detection of pulmonary cryptococcosis cases that cannot be detected using serum antigen tests in patients with small pulmonary lesions. Based on this hypothesis, we examined the performance of the cryptococcal GXM antigen test, in BALF samples, for the diagnosis of pulmonary cryptococcosis.
Methods
This retrospective study was performed for a Japanese, HIV-negative population by reviewing the medical records of patients enrolled in the study. This study was approved by the Nagasaki University School of Medicine Research Ethics Committee (approval number 15032355).
Patients and antigen testing
Between March 2008 and December 2014, 429 patients at the Nagasaki University Hospital were tested for the presence of cryptococcal GXM antigens in their serum and BALF specimens; these individuals constituted the study population. All of these patients underwent bronchoalveolar lavage according to the following method. The lavage was performed, using 20-40 ml of normal saline, in the area of the pulmonary lesion. The aspirated fluid was centrifuged (3000 rpm) for 10 min, and the cell-free supernatant was tested for the presence of cryptococcal GXM antigens; the pellet was cultured and used for cytologic examination. We investigated the diagnostic accuracy of the cryptococcal GXM antigen test, using both serum and BALF samples, for pulmonary cryptococcosis. Data regarding underlying diseases and chest CT findings, such as the presence of nodular lesions or consolidation, single or multiple lesions, maximum lesion diameter, and extension of the bronchial branches into the pulmonary lesion, were also collected from patient records.
A latex agglutination assay (Eiken Kagaku, Tokyo, Japan) was used for the semi-quantitative detection of the cryptococcal GXM antigens. BALF samples (300 μl) were treated with pronase at 56
• C for 30 min, after which the reaction was stopped by heating at 100
• C for 5 min.
Neat samples (75 μl) were mixed with anti-cryptococcal antibody-coated latex (25 μl) and mixed in a shaker (125 ± 25 rev/min) for 10 min. A positive control (50 ng/ml of soluble capsular polysaccharide, isolated from the supernatant of cultured C. neoformans type A) and a negative control (sample diluent) were tested in each assay. When a sample was considered positive, 2-fold serial dilutions were made and assayed using the same procedures to determine the antigen titre. 12 The cut-off value for the cryptococcal GXM antigen titre was ≥1:1, in this study.
Radiological assessment
CT is commonly performed under the Japanese medical insurance system; thus, all of the patients enrolled in this study underwent CT examinations. A radiologist and a respiratory physician independently assessed each patient's CT scans. The maximum diameter of the largest pulmonary lesion was used in the subsequent analyses, if the patient had multiple lesions.
Definition of a pulmonary cryptococcosis diagnosis
Diagnosis of pulmonary cryptococcosis was confirmed with either a positive BALF culture or the presence of C. neoformans in the histopathological or cytological specimens, including BALFs, transbronchial lung biopsies, and CTguided percutaneous lung biopsies. 13 Patients positive for serum cryptococcal GXM antigens, but negative in the culture, histopathologic, or cytologic examinations were defined as "clinically diagnosed"; those with positive BALF antigen results but negative culture, histopathologic, cytologic, and serum cryptococcal GXM antigen results were defined as "possible cases."
Statistical analysis
Correlation significance between cryptococcal GXM antigen titres and the pulmonary lesion size was calculated using Spearman's rank analysis. P-values < .05 indicated statistically significant differences. 
Results

Patient background
Among the 429 patients, 23 were confirmed to have pulmonary cryptococcosis, but cases of cryptococcal cerebromeningitis or positive blood cultures were not observed; all Cryptococcus spp. cultured from these patients were C. neoformans. Lung cancers (74 cases), interstitial pneumonia (31 cases), nontuberculous mycobacterial infection (NTM) (29 cases), and bacterial pneumonia (20 cases) made up the majority of the noncryptococcal diagnoses (Table 1) . No other fungal infections, aside from pulmonary cryptococcosis and aspergillosis, were detected among enrolled the patients. The numbers of confirmed, clinically diagnosed, and possible cases of pulmonary cryptococcosis were 23, 6, and 5, respectively (Table S1-3). Of the 23 confirmed cases, seven (30.4%) had pulmonary symptoms, including coughs, chest pain, and fever. However, of the six clinically diagnosed infections, only one (16.7%) patient demonstrated pulmonary symptoms. Among the 34 study patients, only six did not have underlying disease; among the 28 patients with underlying disease, diabetes mellitus was the most common (34.8%), followed by rheumatoid arthritis (26.1%), solid tumors (8.7%), and hematological malignancies (8.7%). Glucocorticoids and immunosuppressants were administered to 34.8% and 8.2% of the 34 patients, respectively. Sensitivity and specificity of the cryptococcal GXM antigen test Table 2 shows the diagnostic accuracy of the GXM antigen test for each sample type in patients with confirmed pulmonary cryptococcosis; the sensitivity of the cryptococcal GXM antigen test was higher for the BALF samples than for the serum samples. Additionally, if the results of the cryptococcal GXM antigen test for both the serum and BALF samples were used, the sensitivity was higher than it was when only the BALF or serum sample was included. Figure 1 shows the correlation between cryptococcal GXM antigen titers and the pulmonary lesion size. There were positive correlations between the lesion sizes and the antigen titres in both sample types. However, the serum antigen titers showed better correlation (r = 0.490, P = .0033; Spearman's rank correlation) to the lesion size than did the BALF titres (r = 0.312, P = .0724). Figure 2 shows the correlation between the pulmonary lesion size and the rate of positive cryptococcal GXM antigen tests for all patients. The rate of positive samples was higher for BALF tests than for serum tests, especially for pulmonary lesions with diameters ≤25 mm. Five possible cases were detected as a result of positive antigen tests in the BALF samples; the pulmonary lesions were ≤20 mm, in these cases.
CT findings
The CT findings for the 23 confirmed and 11 clinically diagnosed or possible pulmonary cryptococcosis cases were analyzed. The average pulmonary lesion size was largest in the confirmed cases (25.2 ± 19.9 mm) and smallest in the possible cases (13.8 ± 5.1 mm). Among the 34 patients, 10 presented with consolidation (all confirmed cases), whereas 19 or 5 presented with multiple or solitary nodules, respectively. Correlation between the maximum diameter of the largest pulmonary lesion and the rate of positive cryptococcal GXM antigen tests (for confirmed, clinically diagnosed, and possible cases). Black boxes represent confirmed cases, boxes with vertical or slanted lines represent clinically diagnosed or possible cases, respectively. Five possible cases were detected using the BALF cryptococcal GXM antigen test; pulmonary lesions were ≤20 mm in these cases. Consequently, the rate of positive BALF cryptococcal GXM antigen tests was higher than for serum tests.
Cases with positive antigen results only in the BALF samples Table 3 shows the CT findings for patients with positive cryptococcal GXM antigen results in the BALF samples and negative results in the serum samples. Of these, three were confirmed cases and five were possible cases. The average size of the pulmonary lesions was 16.4 ± 5.5 mm, and the CT images revealed that the bronchial branches extended into the lesions in all cases. In six of these eight cases, antifungal agents were administered, and the lesions diminished in size, after treatment. The other two cases received follow-up visits, without medication, and the lesions either grew larger or remained stable (one case each).
Cases positive for GXM in the serum but not in the BALF Among the 23 confirmed cases and 11 clinically diagnosed and possible cases, three cases were positive for cryptococcal GXM antigen in the serum test but negative for the BALF test. Among these patients, the bronchial branches extended into the pulmonary lesion in only one case.
Discussion
Three previously published reports address the diagnostic utility of the cryptococcal GXM antigen in BALF, but its usefulness remains controversial. [14] [15] [16] According to Baughman et al., the cryptococcal GXM antigen test possesses high sensitivity and specificity, in BALF samples, when the titre is ≥1:8 14 ; however, Kralovic et al. did not recommend the routine testing of BALF samples because of the high cost associated with testing the samples. 16 Unlike most of the cases in the previous studies, our patient population included only HIV-negative patients. Specifically, our study reports on the diagnostic utility of cryptococcal GXM antigen assays in BALF samples and the relationship of the test results with chest CT findings in non-HIV patients. The pulmonary lesions size was <25 mm in 27 of the 34 (79.4%) patients in this study. A previous report by Dotsu et al. 9 reported that the sensitivity of a serum cryptococcal GXM antigen test for detecting pulmonary cryptococcosis in patients with small pulmonary lesions was not very high. In addition to the five possible cases, the BALF sample cryptococcal GXM antigen test detected three confirmed cases that were not detected using the serum antigen test. Thus, in this study, the sensitivity of the cryptococcal GXM antigen test for BALF samples was superior to that of the antigen test using serum samples. Additionally, when the cryptococcal GXM antigen was assayed in both serum and BALF samples, the sensitivity was higher than that achieved with either sample type, alone (Table 2) . Antifungal agents were administered to three of the five "possible" cases, and the sizes of pulmonary lesions diminished after treatment (Table 3) . These results may support the accuracy of pulmonary cryptococcosis diagnoses when BALF samples are testing for the presence of cryptococcal GXM antigens. None of the "possible" cases were infected with Trichosporon spp., which cross-reacts with the GXM antigen. 17 In patients who were positive for the GXM antigen in the BALF samples but negative in the serum samples, the pulmonary lesions were not large (mean, 16.4 ± 5.5 mm), possibly explaining the negative results in the serum samples. Although three patients had positive GXM results in their serum samples and negative BALF results, the bronchial branches did not extend into the lesions in two of the three cases. This suggests that CT findings showing the bronchial branches extending into the lesions are crucial for the success of the BALF assays. Technical problems with BALF procurement might be another reason for the negative GXM antigen results in the BALF samples from these patients.
The present results indicate that testing BALF samples for the presence of the cryptococcal GXM antigen may be diagnostically useful, especially for patients with negative serum antigen test results. Therefore, testing for cryptococcal GXM antigens in both serum and BALF samples may enable earlier diagnosis of patients with pulmonary cryptococcosis, potentially avoiding unnecessary invasive procedures. However, this retrospective study has some limitations, including an information bias. Hence, a prospective multicentre study is necessary to further evaluate the performance of the GXM antigen test in BALF samples.
